Join
Live feed
·
PRReleasevia Quantisnow
Tectonic Therapeutic Inc. logo

Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)

ByQuantisnow·Wall Street's wire, on your screen.
TECX· Tectonic Therapeutic Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TECX (Tectonic Therapeutic Inc.) and more on Quantisnow.